ACXP · Acurx Pharmaceuticals, Inc. · Documents

$0.99 -0.05 (-4.37%) At close · Nov 12 Play latest call Q3 2026 earnings call transcript

Market Cap

$5.97M

6.06M

Volume · Nov 12 159.19K Avg daily vol (3M) 124.59K

The company's filings, earnings calls and investor events, most recent first. Search and read these filings from Claude or ChatGPT with the SEC filings MCP server →

Annual report FY2025 Net loss $7.97M 10-K filed Mar 12, 2026 Quarterly report New FY2026 Q3 Net loss $2.58M 10-Q filed Nov 12, 2026 Latest results Financial results 8-K filed May 13, 2025 Earnings call New Q3 2026 earnings call Held Nov 12, 2026

2026

Nov 12

Earnings call

Q3 2026 earnings call AI summary on its way

Nov 12

Quarterly report 10-Q FY2026 Q3, ended Sep 30

Ibezapolstat recurrent-CDI trial enrolls first patient ahead of schedule

Acurx Pharmaceuticals says its ibezapolstat recurrent-CDI pilot enrolled its first patient in the third quarter, ahead of schedule, with up to 20 patients planned. It reported a $6.5 million nine-month net loss and $9.7 million cash as of September 30, 2026.

Net loss $2.58M Diluted EPS -$0.49

Read from the MD&A section

4 source passages

On March 9, 2026, we announced a new clinical development initiative to expand the ibezapolstat program into recurrent C. difficile infection (rCDI). The initiative includes an open label pilot trial in multiply recurrent CDI that will enroll up to 20 patients who have experienced at least 3 CDI episodes within the past 12 months. Trial start-up activities began in the second quarter, and first patient enrollment was originally expected in the fourth quarter of this year. The first patient was enrolled in the third quarter, ahead of schedule. Net loss was $6.5 million for the nine months ended September 30, 2026 and $6.4 million for the nine months ended September 30, 2025, an increase of $0.1 million, due to the reasons stated above. As of September 30, 2026, we had working capital of $7.3 million, consisting primarily of $9.7 million of cash and $0.6 million of prepaid expenses, offset by approximately $3.0 million of accounts payable and accrued expenses. Open the document at this passage

Oct 29

Current report 8-K

Charter or bylaw amendment, or fiscal year change

Acurx Pharmaceuticals, Inc. amended its bylaws effective October 29, 2026, reducing the stockholder quorum to one-third (33⅓%) of outstanding voting power, present in person, by remote communication or by proxy.

Oct 16

Investor event

2026 Annual Meeting of Stockholders

Acurx Pharmaceuticals' 2026 Annual Meeting elected David Luci and Dr. Jack Dean as Class II Directors and ratified CohnResnick LLP as independent auditor for fiscal year ending December 31, 2026, with approximately 52.8 percent quorum present.

Oct 16

Current report 8-K

Shareholder vote results

At its October 16, 2026 Annual Meeting, Acurx Pharmaceuticals stockholders elected David P. Luci and Jack H. Dean as Class II directors for three-year terms expiring in 2029, and ratified CohnReznick LLP as independent auditor for fiscal year ending December 31, 2026.

Sep 8

Registration statement S-1

Registration statement AI summary on its way

Sep 1

Proxy statement DEF 14A Meeting Oct 16, 2026

Proxy statement AI summary on its way

Sep 1

Annual report to holders ARS

Annual report to holders AI summary on its way

Sep 1

Proxy statement DEFA14A

Proxy statement AI summary on its way